Furthermore, TCGA validation of correlations in DLBCL patients confirmed the lack of statistical difference across all the compared groups between IDO1, IDO2, TDO2, and IL4I1 expression and survival rate (Figure 3C), which was consistent with our results. The gene discussed is IL4I1; the disease is diffuse large B-cell lymphoma.